Mode
Text Size
Log in / Sign up
N/A Completed N=36

Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)

Source: ClinicalTrials.gov NCT01445873 ↗
Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcomePrimary: Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Mean Time to Therapy Augmentation — 2.2 months

Summary

The objectives of this study are to develop research methods and corresponding materials for a study of the effectiveness of sitaxentan sodium (Thelin) in "real-world" settings; to pilot test these methods at three study centers in Europe; and to refine and finalize research methods and corresponding materials for possible use in a follow-on, full-scale examination of the effectiveness of sitaxentan sodium (Thelin) in "real-world" settings.

Outcome Measures

OutcomeResultp-value
PRIMARY
Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Mean Time to Therapy Augmentation
2.2 —
PRIMARY
Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Switching
— —
PRIMARY
Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Discontinuation
— —
PRIMARY
Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Therapy Duration
6 —
PRIMARY
Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Numbers of Therapy-days Dispensed
— —
PRIMARY
Patterns of Pharmacotherapy With Sitaxentan Sodium (Thelin): Daily Dosage
100.0 —
SECONDARY
Use of Other Pulmonary Arterial Hypertension (PAH)-Related Medications
83.3; 88.9; 22.2; 5.6; 44.4; 27.8 —
SECONDARY
Change From Baseline in World Health Organization (WHO) Functional Class of Pulmonary Hypertension
0; 0; 0; 0; 0; 1 —
SECONDARY
Change From Baseline in Mean Right Atrial Pressure
-1.3 —
SECONDARY
Change From Baseline in Mean Pulmonary Artery Pressure
— —
SECONDARY
Change From Baseline in Pulmonary Capillary Wedge Pressure
3.0 —
SECONDARY
Change From Baseline in Left Ventricular End Diastolic Pressure
— —
SECONDARY
Change From Baseline in Pulmonary Vascular Resistance
-214.3 —
SECONDARY
Change From Baseline in Cardiac Output
0.4 —
SECONDARY
Change From Baseline in Tei Index
-0.1 —
SECONDARY
Change From Baseline in Tricuspid Regurgitant Velocity
-0.3 —
SECONDARY
Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT)
28.5 —
SECONDARY
Change From Baseline in Borg Dyspnoea Score
4.9 —
SECONDARY
Change From Baseline in Percent of Predicted Peak VO2
3.5 —
SECONDARY
Pulmonary Arterial Hypertension (PAH) Severity and Functional Status: Time to Clinical Worsening
2.8 —
SECONDARY
Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Mortality
— —
SECONDARY
Number of Hospitalizations
0.5 —
SECONDARY
Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Lung Transplantation
— —
SECONDARY
Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Heart/Lung Transplantation
— —
SECONDARY
Other Pulmonary Arterial Hypertension (PAH)-Related Outcomes: Atrial Septostomy
— —

Eligibility Criteria

Inclusion Criteria

  • Idiopathic PAH, or PAH secondary to connective tissue disease
  • Receipt of Thelin for treatment of PAH
  • 6 months of follow-up (except in the event of death) subsequent to initial receipt of Thelin
  • Minimum of one clinic visit documented in the medical record during the 6-month period subsequent to initial receipt of Thelin

Exclusion Criteria

  • Participation in any investigational study of Thelin or any other medication for the treatment of PAH during the period beginning 6 months prior to initial receipt of Thelin and ending 6 months subsequent to such receipt
  • Receipt of Thelin prior to January 11, 2005 (i.e., the date following the last day on which patients could be enrolled in double-blind treatment in STRIDE-1, STRIDE-2, and/or STRIDE-6); or
  • Known contraindications to Thelin therapy (i.e., known hypersensitivity to sitaxsentan or any of its excipients; mild-to-severe hepatic impairment [Child-Pugh Class A-C]; elevated aminotransferases prior to initiation of treatment, defined as aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] >3 times upper limit of normal [ULN]; concomitant use of cyclosporin A; lactation)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01445873). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search